Yan-Qun Xiang (Yanqun Xiang)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 15

Top Venues

BMJ (Clinical research ed.)

Nature communications

Cancer management and research

Journal of inflammation research

Sun Yat-Sen University (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Sun Yat-Sen University Sep 01 2001 - Jun 30 2004

China

PHD

Publications

Guo-Ying Liu, Yan-Fang Ye, Yao-Fei Jiang, Gina Jinna Chen, Wei-Xiong Xia, Yi-Sheng Huang, Tian-Sheng Gao, Yi-Min Liu, Ya-Ting Hou, Jian-Fei Li, Jia-Hao Liu, Nian Lu, Chang-Long Chen, Liang-Ru Ke, Hu Liang, Wei-Xin Bei, Wang-Zhong Li, Shu-Hui Dong, Qin Liu, Changqing Xie, He-Rui Yao, Yan-Qun Xiang
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. BMJ (Clinical research ed.) 385 (2024)
Guo-Ying Liu, Yan-Fang Ye, Yao-Fei Jiang, Gina Jinna Chen, Wei-Xiong Xia, Yi-Sheng Huang, Tian-Sheng Gao, Yi-Min Liu, Ya-Ting Hou, Jian-Fei Li, Jia-Hao Liu, Nian Lu, Chang-Long Chen, Liang-Ru Ke, Hu Liang, Wei-Xin Bei, Wang-Zhong Li, Shu-Hui Dong, Qin Liu, Changqing Xie, He-Rui Yao, Yan-Qun Xiang
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. BMJ (Clinical research ed.) 385 (2024)
Hu Liang, Yao-Fei Jiang, Guo-Ying Liu, Lin Wang, Jian-Wei Wang, Nian Lu, Wei-Xiong Xia, Liang-Ru Ke, Yan-Fang Ye, Jin-Lin Duan, Wei-Xin Bei, Shu-Hui Dong, Wang-Zhong Li, Li-Ting Liu, Chong Zhao, Changqing Xie, Yan-Qun Xiang
Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial. Nature communications 15 (1) (2024)
Guo-Ying Liu, Yan-Fang Ye, Yao-Fei Jiang, Gina Jinna Chen, Wei-Xiong Xia, Yi-Sheng Huang, Tian-Sheng Gao, Yi-Min Liu, Ya-Ting Hou, Jian-Fei Li, Jia-Hao Liu, Nian Lu, Chang-Long Chen, Liang-Ru Ke, Hu Liang, Wei-Xin Bei, Wang-Zhong Li, Shu-Hui Dong, Qin Liu, Changqing Xie, He-Rui Yao, Yan-Qun Xiang
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. BMJ (Clinical research ed.) 385 (2024)
Guo-Ying Liu, Yan-Fang Ye, Yao-Fei Jiang, Gina Jinna Chen, Wei-Xiong Xia, Yi-Sheng Huang, Tian-Sheng Gao, Yi-Min Liu, Ya-Ting Hou, Jian-Fei Li, Jia-Hao Liu, Nian Lu, Chang-Long Chen, Liang-Ru Ke, Hu Liang, Wei-Xin Bei, Wang-Zhong Li, Shu-Hui Dong, Qin Liu, Changqing Xie, He-Rui Yao, Yan-Qun Xiang
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. BMJ (Clinical research ed.) 385 (2024)
Weixin Bei, Shuhui Dong, Guoying Liu, Lanfeng Lin, Yaofei Jiang, Nian Lu, Wangzhong Li, Hu Liang, Yan-Qun Xiang, Weixiong Xia
Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors. Cancer management and research 16 (2024)
Guo-Ying Liu, Yan-Fang Ye, Yao-Fei Jiang, Gina Jinna Chen, Wei-Xiong Xia, Yi-Sheng Huang, Tian-Sheng Gao, Yi-Min Liu, Ya-Ting Hou, Jian-Fei Li, Jia-Hao Liu, Nian Lu, Chang-Long Chen, Liang-Ru Ke, Hu Liang, Wei-Xin Bei, Wang-Zhong Li, Shu-Hui Dong, Qin Liu, Changqing Xie, He-Rui Yao, Yan-Qun Xiang
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. BMJ (Clinical research ed.) 385 (2024)
Weixin Bei, Shuhui Dong, Guoying Liu, Lanfeng Lin, Yaofei Jiang, Nian Lu, Wangzhong Li, Hu Liang, Yan-Qun Xiang, Weixiong Xia
Efficacy and Safety of Re-Challenging PD-1 Inhibitors in Second-Line Treatment in Metastatic Nasopharyngeal Carcinoma Previously Treated with Chemotherapy and PD-1 Inhibitors. Cancer management and research 16 (2024)
Hu Liang, Yao-Fei Jiang, Guo-Ying Liu, Lin Wang, Jian-Wei Wang, Nian Lu, Wei-Xiong Xia, Liang-Ru Ke, Yan-Fang Ye, Jin-Lin Duan, Wei-Xin Bei, Shu-Hui Dong, Wang-Zhong Li, Li-Ting Liu, Chong Zhao, Changqing Xie, Yan-Qun Xiang
Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial. Nature communications 15 (1) (2024)
Guo-Ying Liu, Yan-Fang Ye, Yao-Fei Jiang, Gina Jinna Chen, Wei-Xiong Xia, Yi-Sheng Huang, Tian-Sheng Gao, Yi-Min Liu, Ya-Ting Hou, Jian-Fei Li, Jia-Hao Liu, Nian Lu, Chang-Long Chen, Liang-Ru Ke, Hu Liang, Wei-Xin Bei, Wang-Zhong Li, Shu-Hui Dong, Qin Liu, Changqing Xie, He-Rui Yao, Yan-Qun Xiang
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. BMJ (Clinical research ed.) 385 (2024)
Hu Liang, Yao-Fei Jiang, Guo-Ying Liu, Lin Wang, Jian-Wei Wang, Nian Lu, Wei-Xiong Xia, Liang-Ru Ke, Yan-Fang Ye, Jin-Lin Duan, Wei-Xin Bei, Shu-Hui Dong, Wang-Zhong Li, Li-Ting Liu, Chong Zhao, Changqing Xie, Yan-Qun Xiang
Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial. Nature communications 15 (1) (2024)
Shu-Hui Lv, Wang-Zhong Li, Hu Liang, Guo-Ying Liu, Wei-Xiong Xia, Yan-Qun Xiang
Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy. Journal of inflammation research 14 (2021)
Wang-Zhong Li, Xin Hua, Shu-Hui Lv, Hu Liang, Guo-Ying Liu, Nian Lu, Wei-Xin Bei, Wei-Xiong Xia, Yan-Qun Xiang
A Scoring System Based on Nutritional and Inflammatory Parameters to Predict the Efficacy of First-Line Chemotherapy and Survival Outcomes for De Novo Metastatic Nasopharyngeal Carcinoma. Journal of inflammation research 14 (2021)
Wang-Zhong Li, Guo-Ying Liu, Shu-Hui Lv, Sen-Kui Xu, Hu Liang, Kui-Yuan Liu, Meng-Yun Qiang, Xi Chen, Xiang Guo, Xing Lv, Wei-Xiong Xia, Yan-Qun Xiang
Educational disparities in nasopharyngeal carcinoma survival: Temporal trends and mediating effects of clinical factors. Clinical and translational medicine 10 (3) (2020)
Guo-Ying Liu, Wang-Zhong Li, Kang-Qiang Peng, Xing Lv, Liang-Ru Ke, Yi-Shan Wu, De-Ling Wang, Hu Liang, Kui-Yuan Liu, Shu-Hui Lv, Xiang Guo, Yan-Qun Xiang, Wei-Xiong Xia
Prognostic value of early radiological response to first-line platinum-containing chemotherapy in patients with metastatic nasopharyngeal carcinoma. Cancer medicine 9 (3) (2019)

Yan-Qun Xiang.css-eqlu8i{font-size:small;padding-left:4px;} (Yanqun Xiang)

Publication Activity (10 Years)

Top Topics

Top Venues

Yan-Qun Xiang (Yanqun Xiang)